Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy

Ahmed, Shwan; Lindsey, Bronagh; Davies, John

doi:10.1038/sj.pcan.4500774

Cited by 27 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,7 Cryosurgery has emerged as one of the many tools available for the treatment of CaP. 5,8 This procedure utilizes the destructive forces of low temperature to ablate unwanted tissue. [9][10][11][12] The center (nearest the cryoprobe) of the cryogenic legion is rendered completely necrotic, but as temperatures elevate further from the probe tip, less is known about the mechanisms of cell death and survival.…”

Section: Introductionmentioning

confidence: 99%

Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer

Clarke

Robilotto

VanBuskirk

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Adjuvant therapies contribute to the successful treatment of cancer. Our previous reports have shown that combining cryoablation with cytotoxic agents enhances cell death. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytotoxic agent that preferentially induces apoptosis in a variety of human cancer cells. Human prostate cancer cells (PC-3) are resistant to many cytodestructive agents, including cryoablation and TRAIL. Here, we evaluated the effects of TRAIL combined with cryoablation on PC-3 and normal prostate (RWPE-1) cell death. Exposure of PC-3 cells to freezing (À101C) or TRAIL (500ng/ml) results in minimal cell death, whereas a complete loss of viability is observed with the simultaneous combination. The synergistic effect was found to be due to a marked increase in apoptosis. Western blot analysis revealed a significant level of caspase-8 and -3 cleavage between 12 and 24 h post-exposure. Caspase activation assays provided similar results and also indicated a role for caspase-9. Inhibitors to caspase-8 and -9 along with a pan-caspase inhibitor were incorporated to determine which pathway was necessary for the combined efficacy. Inhibition of caspase-8 significantly blocked the combination-induced cell death compared to cells that did not receive the inhibitor (63% compared to 10% viable). The addition of the caspase-9 inhibitor resulted in only a minimal protection. Importantly, the combination was not effective when applied to normal prostate cells. The results describe a novel therapeutic model for the treatment of prostate cancer and provide support for future in vivo studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer

Clarke

Robilotto

VanBuskirk

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…6 The introduction of third-generation cryotechnology (Oncura Inc., Plymouth Meeting, PA) using 17-guage ultrathin cryoneedles and an argon-helium gas system, and recent modifications in the technique of salvage cryoablation have enabled cryosurgeons to treat these tumors safely and with significantly decreased morbidity. [10][11][12][13][14][15][16][17] The results of a large database (963 patients) after primary and salvage procedures from Allegheny General Hospital (AGH) demonstrated 10-year undetectable PSA -response to salvage cryoablation as approximately 60%, that is, comparable to the results of salvage radical prostatectomy. 13 Furthermore, Cohen demonstrated the rate of certain complications has dramatically decreased with time due to improvements in technology and techniques when comparing first and second versus third-generation equipment: urethral sloughing (from 14 to 2%), incontinence (from 3.2 to 0%), and prostate stones (from 4 to 0%), respectively.…”

Section: Discussionmentioning

confidence: 99%

Salvage prostate cryoablation after primary interstitial brachytherapy failure: a feasible approach

Mouraviev

Evans

Polascik

2005

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

“…[30] Additionally, the use of a warming catheter and improved catheterization techniques have reduced urethral sloughing and stricture rates from 10-15% to as low as 0%. [31,32] Impotence remains an accepted side effect of wholeprostate SCA. Focal subtotal SCA can be offered to the rare patient who is potent and has a limited number of positive biopsy cores.…”

Section: Salvage Cryoablationmentioning

confidence: 99%

Salvage therapies for radiorecurrent prostate cancer

Mustafa

Pisters²

2011

Turkish Journal of Urology

View full text Add to dashboard Cite

Locally recurrent prostate cancer after radiation therapy, also known as radiorecurrent prostate cancer, has an unfavorable prognosis. Two-thirds of patients with radiorecurrent prostate cancer have an advanced pathological disease status by the time they undergo salvage therapy. Several salvage therapies for radiorecurrent prostate cancer are available. Salvage radical prostatectomy (SRP) and salvage cryoablation are the most feasible and effective therapies for radiorecurrent prostate cancer. Although SRP is technically more difficult and has a higher complication rate than do other salvage therapies, the procedure provides a long-term survival benefit. Preliminary studies of salvage robot-assisted radical prostatectomy (SRARP) suggest that SRARP may be similar to or at least as effective as SRP. The intermediate oncological efficacy and morbidity of salvage cryoablation are similar to those of SRP. Prognostic factors for successful salvage therapy include serum prostate-specific antigen level ≤10 ng/mL, Gleason score ≤8, and a clinical disease stage T1c or T2. Assessing the comparative oncological efficacy and complications of the available salvage therapies for radiorecurrent prostate cancer requires strict guidelines, including universal patient selection criteria and an intergrade definition of biochemical failure.

show abstract

Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy

Cited by 27 publications

References 36 publications

Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer

Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer

Salvage prostate cryoablation after primary interstitial brachytherapy failure: a feasible approach

Salvage therapies for radiorecurrent prostate cancer

Contact Info

Product

Resources

About